Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

MD Anderson announces licensing agreements with BostonGene and Tempus for its EGFR Classification

The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson EGFR Classification, which groups EGFR mutations in non-small cell lung cancer (NSCLC) based on structural modifications and sensitivity to available therapies.

19 Jan 2023

Study finds wide variation in the quality of care for lung cancer across the U.S.

Treatment for lung cancer is rapidly evolving, with new technologies and research-proven procedures.

18 Jan 2023

Novel bacterial therapy approach opens up new treatment options for lung cancer patients

Lung cancer is the deadliest cancer in the United States and around the world. Many of the currently available therapies have been ineffective, leaving patients with very few options.

26 Dec 2022

New imaging agent lights the way for surgeons during lung cancer surgery

Surgery, especially surgery to remove cancerous tumors, relies on a range of tools and techniques as well as on the skill of the surgeon.

19 Dec 2022

Study suggests new anti-KRAS drug as a strong candidate for pancreatic cancer clinical trials

A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine's Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials.

6 Dec 2022

Study explores practical pathways to motherhood in women with oncogene-driven lung cancer

New research from the University of Colorado (CU) Cancer Center highlights the need for additional data collection for women hoping to have successful pregnancies while undergoing treatment for lung cancer.

5 Dec 2022

Frequent surveillance imaging not linked to better outcomes following lung cancer surgery

Regular postsurgical screening is critical for patients with lung cancer, the United States' second most prevalent type of cancer and leading cause of cancer deaths.

28 Nov 2022

Simultaneous radiation and immunotherapy can benefit mNSCLC patients with high tumor aneuploidy

In many cancer types, cancer cells try to survive by escaping attack from the immune system. These cancer cells hijack mechanisms called immune checkpoints to trick the immune system into thinking they are healthy cells.

28 Nov 2022

Research findings could bolster the effectiveness of immune-checkpoint therapy

Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system's T cells to attack tumor cells.

16 Nov 2022

New breakthrough could help spot lung cancer earlier and improve patient outcomes

Scientists investigating the mechanics of the early stages of lung cancer have identified a new potential treatment, which could also aid early detection of the disease.

8 Nov 2022

Minorities with common form of lung cancer face longer wait times for receiving radiation therapy

A new study has revealed significant racial disparities in how quickly minorities with the most common form of lung cancer receive potentially lifesaving radiation therapy compared with their white counterparts.

25 Oct 2022

Phase III ADAURA trial reveals promising results for patients with non-small cell lung cancer

Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years.

12 Sep 2022

Study identifies new therapeutic target against lung adenocarcinoma

The TIMP-1 protein levels in both tissues and blood have been repeatedly associated with a poor prognosis in lung cancers, but its role in this cancer process was, to date, unknown.

12 Sep 2022

Pollutant particles in the air trigger lung cancer in non-smokers

A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies, according to late-breaking data [to be] reported at the ESMO Congress 2022 by scientists of the Francis Crick Institute and University College London, funded by Cancer Research UK. The particles, which are typically found in vehicle exhaust and smoke from fossil fuels, are associated with non-small cell lung cancer (NSCLC) risk, accounting for over 250,000 lung cancer deaths globally per year.

12 Sep 2022

Comprehensive genetic architecture atlas compiled for mutant RAS genes in cancers

Researchers at the Johns Hopkins Kimmel Cancer Center, three other cancer centers and the Johns Hopkins Bloomberg School of Public Health compiled a comprehensive genetic architecture atlas for mutant RAS genes in human cancers.

8 Sep 2022

CRISPR genome-editing technology can be used as a tool to discover RNA therapeutics for lung cancer

An international team of scientists have demonstrated for the first time that CRISPR genome-editing technology can be used as a tool to find new gene therapies for lung cancer.

24 Aug 2022

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment.

8 Aug 2022

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.

8 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Non Small Cell Lung Cancer News and Research

MD Anderson announces licensing agreements with BostonGene and Tempus for its EGFR Classification

Study finds wide variation in the quality of care for lung cancer across the U.S.

Novel bacterial therapy approach opens up new treatment options for lung cancer patients

New imaging agent lights the way for surgeons during lung cancer surgery

Study suggests new anti-KRAS drug as a strong candidate for pancreatic cancer clinical trials

Study explores practical pathways to motherhood in women with oncogene-driven lung cancer

Frequent surveillance imaging not linked to better outcomes following lung cancer surgery

Simultaneous radiation and immunotherapy can benefit mNSCLC patients with high tumor aneuploidy

Research findings could bolster the effectiveness of immune-checkpoint therapy

New breakthrough could help spot lung cancer earlier and improve patient outcomes

Minorities with common form of lung cancer face longer wait times for receiving radiation therapy

Phase III ADAURA trial reveals promising results for patients with non-small cell lung cancer

Study identifies new therapeutic target against lung adenocarcinoma

Pollutant particles in the air trigger lung cancer in non-smokers

Comprehensive genetic architecture atlas compiled for mutant RAS genes in cancers

CRISPR genome-editing technology can be used as a tool to discover RNA therapeutics for lung cancer

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News